Baker Avenue Asset Management, LP Vaxcyte, Inc. Transaction History
Baker Avenue Asset Management, LP
- $3.21 Billion
- Q1 2025
A detailed history of Baker Avenue Asset Management, LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 13,144 shares of PCVX stock, worth $432,043. This represents 0.02% of its overall portfolio holdings.
Number of Shares
13,144
Previous 13,143
0.01%
Holding current value
$432,043
Previous $1.08 Million
53.86%
% of portfolio
0.02%
Previous 0.03%
Shares
6 transactions
Others Institutions Holding PCVX
# of Institutions
345Shares Held
136MCall Options Held
348KPut Options Held
250K-
Ra Capital Management, L.P. Boston, MA12.2MShares$401 Million9.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$396 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X011.8MShares$387 Million0.25% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$327 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA6.42MShares$211 Million0.05% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $1.95B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...